RxDoctor Payments Data

William Deluccia, MD

Cardiovascular Disease · Elmira, NYNPI 1568493112

Payments from drug & device makers

$642in general payments, 2019–2025

Across 36 payments — averaging $17.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$254
  • Novartis$113
  • Amgen$46
  • Vifor Pharma, Inc.$40
  • Kowa Pharmaceuticals America, Inc.$35
  • Johnson & Johnson$33
  • plus $121 from 7 others

What the payments were for

  • Food & beverage$54385%
  • Education$9915%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$642 in reported general payments places this provider in the 30th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$126,466
Medicare patients
767
Services billed
1,527

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban697$792,843
XareltoRivaroxaban236$251,105
JardianceEmpagliflozin174$192,099
Repatha SureclickEvolocumab124$112,297
EntrestoSacubitril/Valsartan81$104,996
Praluent PenAlirocumab85$50,391
BrilintaTicagrelor33$26,921
Metoprolol Succinate1,112$19,010
VascepaIcosapent Ethyl15$13,440
Ezetimibe299$10,257
Ranolazine ErRanolazine94$9,735
Repatha SyringeEvolocumab15$7,952
Dofetilide14$7,649
Potassium Chloride379$7,411
Torsemide346$7,302

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$33$251,105236 claims
Boehringer IngelheimJardiance$15$192,099174 claims
NovartisEntresto$113$104,99681 claims
AstraZenecaBrilinta$24$26,92133 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Elmira

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →